PMID- 30758417
OWN - NLM
STAT- MEDLINE
DCOM- 20190312
LR  - 20190312
IS  - 1806-9282 (Electronic)
IS  - 0104-4230 (Linking)
VI  - 65
IP  - 1
DP  - 2019 Jan
TI  - The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver 
      disease: preliminary data.
PG  - 33-37
LID - S0104-42302019000100033 [pii]
LID - 10.1590/1806-9282.65.1.33 [doi]
AB  - OBJECTIVE: To investigate the clinical efficacy and the possible mechanisms of 
      saxagliptin in the treatment of type 2 diabetes mellitus (T2DM) combined with 
      non-alcoholic fatty liver disease (NAFLD). METHODS: A total of 95 T2DM and NAFLD 
      patients were randomly divided into group A (saxagliptin group), group B 
      (glimepiride group), and group C (glimepiride combined with polyene 
      phosphatidylcholine group). RESULTS: After intervention treatment for 24 w, body 
      mass index (BMI), waist-to-hip ratio (WHR), glycated haemoglobin (HbA1c), fasting 
      plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment of 
      insulin resistance (HOMA-IR), interleukin-6 (IL-6), triglyceride (TG), total 
      cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase 
      (AST), gamma-glutamyltransferase (gamma-GT), and quantitative detection of liver 
      steatosis of study subjects were observed, the action of liver steatosis in 
      subjects of groups A and C were significantly different from those of group B; 
      however, there were no differences between groups A and C. The FINS, HOMA-IR, and 
      IL-6 of subjects in group A was lower than those in groups B and C; however, 
      there were no significant differences between the latter two groups. CONCLUSION: 
      For T2DM combined with NAFLD patients, the saxagliptin treatment could not only 
      effectively control blood glucose but also attenuate insulin resistance and 
      inflammatory injury of the liver to improve fatty liver further.
FAU - Li, Juan-Juan
AU  - Li JJ
AUID- ORCID: 0000-0002-4165-5981
AD  - Health Management Center, Qilu Hospital of Shandong University (Qingdao), 
      Shandong Province, China.
FAU - Zhang, Ping
AU  - Zhang P
AUID- ORCID: 0000-0001-6214-557X
AD  - Department of Ultrasonography, Qilu Hospital of Shandong University (Qingdao), 
      Shandong Province, China.
FAU - Fan, Bing
AU  - Fan B
AUID- ORCID: 0000-0001-8007-2036
AD  - Health Management Center, Qilu Hospital of Shandong University (Qingdao), 
      Shandong Province, China.
FAU - Guo, Xiu-Li
AU  - Guo XL
AUID- ORCID: 0000-0003-0831-0516
AD  - Department of Ultrasonography, Qilu Hospital of Shandong University (Qingdao), 
      Shandong Province, China.
FAU - Zheng, Zhe-Shu
AU  - Zheng ZS
AUID- ORCID: 0000-0002-1379-3068
AD  - Department of Ultrasonography, Qilu Hospital of Shandong University (Qingdao), 
      Shandong Province, China.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Phosphatidylcholines)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (polyene phosphatidylcholine)
RN  - 6KY687524K (glimepiride)
RN  - 9GB927LAJW (saxagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/administration & dosage/*analogs & derivatives
MH  - Blood Glucose
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Dipeptides/*administration & dosage
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/complications/*drug therapy
MH  - Phosphatidylcholines/*administration & dosage
MH  - Sulfonylurea Compounds/*administration & dosage
MH  - Treatment Outcome
EDAT- 2019/02/14 06:00
MHDA- 2019/03/13 06:00
CRDT- 2019/02/14 06:00
PHST- 2018/08/09 00:00 [received]
PHST- 2018/08/27 00:00 [accepted]
PHST- 2019/02/14 06:00 [entrez]
PHST- 2019/02/14 06:00 [pubmed]
PHST- 2019/03/13 06:00 [medline]
AID - S0104-42302019000100033 [pii]
AID - 10.1590/1806-9282.65.1.33 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 2019 Jan;65(1):33-37. doi: 10.1590/1806-9282.65.1.33.